Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat...
September 09, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Oral and Poster Presentations at the International Conference on Complement Therapeutics

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented data at the International Conference on Complement Therapeutics (ICCT),...
September 08, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Appointment of Jeanne Jew to its Board of Directors

Seasoned Biopharmaceutical Executive Adds Substantial Corporate Development Expertise SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today...
August 05, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30,...
July 22, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies

SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the screening of the first patient in its CFI-deficiency study in the CB 4332...
July 19, 2021 16:01 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress

SOUTH SAN FRANCISCO, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented four posters at the International Society for Thrombosis and Haemostasis...
July 14, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company

Grant Blouse, Ph.D., M.Sc. appointed chief scientific officer Tom Knudsen, DVM, Ph.D. promoted to senior vice president, corporate development Howard Levy, M.B.B.Ch, Ph.D., M.M.M. transitions to...
July 06, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis

SOUTH SAN FRANCISCO, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced four poster presentations on marzaptacog alfa (activated) (MarzAA) and...
July 01, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs

SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development day on its protease medicines...
June 28, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track...